Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
Under an Elsevier user license
open archive
Keywords
Predictive model
Angiotensin
Vascular normalization
Immune activation
Anti-angiogenic treatment
Glioblastoma
Antigen presentation
Abbreviations
VEGF
vascular endothelial growth factor A
C-index
concordance index
AGT
angiotensinogen
HLA-DQA1
human leukocyte antigen complex class II DQ alpha 1
IDH1
isocitrate dehydrogenase 1
Cited by (0)
© 2016 Federation of European Biochemical Societies. Published by Elsevier B.V.